High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia
Authors:
- 31 July 2008
- journal article
- research article
- Published by Elsevier in Schizophrenia Research
- Vol. 102 (1-3) , 88-95
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross‐over studyHuman Psychopharmacology: Clinical and Experimental, 2004
- Effects of Nicotine on Cognitive Deficits in SchizophreniaNeuropsychopharmacology, 2004
- Evidence of Association between Smoking and α7 Nicotinic Receptor Subunit Gene in Schizophrenia PatientsNeuropsychopharmacology, 2004
- Nicotine effects on brain function and functional connectivity in schizophreniaBiological Psychiatry, 2004
- Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependentLife Sciences, 2003
- Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine ReceptorsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophreniaSchizophrenia Research, 2003
- Association of Promoter Variants in the α7 Nicotinic Acetylcholine Receptor Subunit Gene With an Inhibitory Deficit Found in SchizophreniaArchives of General Psychiatry, 2002
- A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophreniaInternational Journal of Neuropsychopharmacology, 1999
- Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophreniaNeuroscience Letters, 1980